Sven C van Dijkman1, Nico C B de Jager1, Willem M Rauwé1, Meindert Danhof1, Oscar Della Pasqua2,3,4. 1. Division of Pharmacology, Leiden Academic Centre for Drug Research, Einsteinweg 55, 2333CC, Leiden, The Netherlands. 2. Division of Pharmacology, Leiden Academic Centre for Drug Research, Einsteinweg 55, 2333CC, Leiden, The Netherlands. oscar.e.della-pasqua@gsk.com. 3. Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Uxbridge, UB11 1BT, UK. oscar.e.della-pasqua@gsk.com. 4. Clinical Pharmacology and Therapeutics Group, University College London, BMA House (North Entrance), Tavistock Square, London, WC1H 9JP, UK. oscar.e.della-pasqua@gsk.com.
Abstract
BACKGROUND AND AIMS: In this study, we evaluate the performance of allometric concepts to predict the implications of age and size on the pharmacokinetics of lamotrigine, and assess the dose rationale across different age groups from 0.2 to 91 years. METHODS: An allometrically scaled pharmacokinetic model was developed using adolescent and adult data, taking into account the effect of comedications. Model parameters were then used to extrapolate lamotrigine pharmacokinetics to older adults (> 65 years), children (4-12 years) and infants and toddlers (0.2-2.0 years). In addition, simulations were performed to identify the implication of different doses and dosing regimens for each population, so as to ensure steady-state concentrations within a predefined reference range. RESULTS: The pharmacokinetics of lamotrigine was best described using a one-compartment model with first-order absorption and elimination. Carbamazepine, phenytoin, and valproic acid changed systemic clearance (CL) by + 76.5, + 129, and - 47.4%, respectively. Allometric principles allowed accurate extrapolation of disposition parameters to older adults and children older than 4 years of age. A maturation function was required to describe changes in exposure in younger patients. Compared with adults, a child aged 1.7 years has a 31.5% higher CL, after correcting for body weight. Patients > 65 years of age showed a decrease in CL of approximately 15%. CONCLUSION: Population pharmacokinetic models are usually limited to a subgroup of patients, which may mask the identification of factors contributing to interindividual variability. The availability of an integrated model including the whole patient population provides insight into the role of age-related changes in the disposition of lamotrigine, and potential implications for maintenance dose optimisation in any future trials. TRIAL REGISTRATION: According to GlaxoSmithKline's Clinical Trial Register, data from the GlaxoSmithKline studies LAM100034 and LEP103944, corresponding to ClinicalTrials.gov identifiers NCT00113165 and NCT00264615, used in this work, have been used in previous publications (doi: https://doi.org/10.1212/01.wnl.0000277698.33743.8b , https://doi.org/10.1111/j.1528-1167.2007.01274.x ).
BACKGROUND AND AIMS: In this study, we evaluate the performance of allometric concepts to predict the implications of age and size on the pharmacokinetics of lamotrigine, and assess the dose rationale across different age groups from 0.2 to 91 years. METHODS: An allometrically scaled pharmacokinetic model was developed using adolescent and adult data, taking into account the effect of comedications. Model parameters were then used to extrapolate lamotrigine pharmacokinetics to older adults (> 65 years), children (4-12 years) and infants and toddlers (0.2-2.0 years). In addition, simulations were performed to identify the implication of different doses and dosing regimens for each population, so as to ensure steady-state concentrations within a predefined reference range. RESULTS: The pharmacokinetics of lamotrigine was best described using a one-compartment model with first-order absorption and elimination. Carbamazepine, phenytoin, and valproic acid changed systemic clearance (CL) by + 76.5, + 129, and - 47.4%, respectively. Allometric principles allowed accurate extrapolation of disposition parameters to older adults and children older than 4 years of age. A maturation function was required to describe changes in exposure in younger patients. Compared with adults, a child aged 1.7 years has a 31.5% higher CL, after correcting for body weight. Patients > 65 years of age showed a decrease in CL of approximately 15%. CONCLUSION: Population pharmacokinetic models are usually limited to a subgroup of patients, which may mask the identification of factors contributing to interindividual variability. The availability of an integrated model including the whole patient population provides insight into the role of age-related changes in the disposition of lamotrigine, and potential implications for maintenance dose optimisation in any future trials. TRIAL REGISTRATION: According to GlaxoSmithKline's Clinical Trial Register, data from the GlaxoSmithKline studies LAM100034 and LEP103944, corresponding to ClinicalTrials.gov identifiers NCT00113165 and NCT00264615, used in this work, have been used in previous publications (doi: https://doi.org/10.1212/01.wnl.0000277698.33743.8b , https://doi.org/10.1111/j.1528-1167.2007.01274.x ).
Authors: Ron J Keizer; Michel van Benten; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema Journal: Comput Methods Programs Biomed Date: 2010-06-02 Impact factor: 5.428
Authors: Sven C van Dijkman; Sebastian G Wicha; Meindert Danhof; Oscar E Della Pasqua Journal: Clin Pharmacol Ther Date: 2017-08-30 Impact factor: 6.875
Authors: Sven C van Dijkman; Nico C B de Jager; Willem M Rauwé; Meindert Danhof; Oscar Della Pasqua Journal: Clin Pharmacokinet Date: 2018-11 Impact factor: 6.447
Authors: Joseph F Standing; Brian J Anderson; Stefanie Hennig; Nick H Holford; Trevor N Johnston; Catherijne A J Knibbe; Dagan O Lonsdale; Amin Rostami-Hodjegan Journal: Clin Pharmacokinet Date: 2018-11 Impact factor: 6.447
Authors: Carla Liaci; Lucia Prandi; Lisa Pavinato; Alfredo Brusco; Mara Maldotti; Ivan Molineris; Salvatore Oliviero; Giorgio R Merlo Journal: Int J Mol Sci Date: 2022-05-30 Impact factor: 6.208
Authors: Anna K Eigenbrodt; Håkan Ashina; Sabrina Khan; Hans-Christoph Diener; Dimos D Mitsikostas; Alexandra J Sinclair; Patricia Pozo-Rosich; Paolo Martelletti; Anne Ducros; Michel Lantéri-Minet; Mark Braschinsky; Margarita Sanchez Del Rio; Oved Daniel; Aynur Özge; Ayten Mammadbayli; Mihails Arons; Kirill Skorobogatykh; Vladimir Romanenko; Gisela M Terwindt; Koen Paemeleire; Simona Sacco; Uwe Reuter; Christian Lampl; Henrik W Schytz; Zaza Katsarava; Timothy J Steiner; Messoud Ashina Journal: Nat Rev Neurol Date: 2021-06-18 Impact factor: 42.937